{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:01:11Z","timestamp":1762909271786,"version":"3.45.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019803","name":"Oklahoma State University Center for Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.resmer.2022.100962","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T01:27:36Z","timestamp":1665278856000},"page":"100962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-3287","authenticated-orcid":false,"given":"Ty","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danya","family":"Nees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Hightower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Heigle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Ottwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Hartwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2022.100962_bib0001","article-title":"Cystic fibrosis year in review 2020: section 2 pulmonary disease, infections, and inflammation","author":"Antos","year":"2021","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0003","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International committee on mental health in cystic fibrosis: cystic fibrosis foundation and European cystic fibrosis society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.resmer.2022.100962_bib0004","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4187\/respcare.06356","article-title":"Health-related quality of life in adolescents and adults with cystic fibrosis: physical and mental health predictors","volume":"64","author":"Cronly","year":"2019","journal-title":"Respir Care"},{"issue":"2","key":"10.1016\/j.resmer.2022.100962_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17476348.2017.1280399","article-title":"Adherence to therapies in cystic fibrosis: a targeted literature review","volume":"11","author":"Narayanan","year":"2017","journal-title":"Expert Rev Respir Med"},{"issue":"12","key":"10.1016\/j.resmer.2022.100962_bib0006","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ppul.23554","article-title":"Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis","volume":"51","author":"Levy","year":"2016","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.resmer.2022.100962_bib0007","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jval.2012.12.003","article-title":"Understanding the costs of care for cystic fibrosis: an analysis by age and health state","volume":"16","author":"van Gool","year":"2013","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.resmer.2022.100962_bib0008","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jcf.2020.08.015","article-title":"Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: a systematic review","volume":"19","author":"McLeod","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.resmer.2022.100962_bib0009","first-page":"146","article-title":"Utilization of patient-reported outcomes as a step towards collaborative medicine","volume":"14","author":"Blackwell","year":"2013","journal-title":"Paediatr Respir Rev"},{"issue":"5","key":"10.1016\/j.resmer.2022.100962_bib0010","doi-asserted-by":"crossref","first-page":"e15467","DOI":"10.2196\/15467","article-title":"Patient-reported outcome measures in cystic fibrosis: protocol for a systematic review","volume":"9","author":"Ratnayake","year":"2020","journal-title":"JMIR Res Protoc"},{"issue":"10","key":"10.1016\/j.resmer.2022.100962_bib0011","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","article-title":"A systematic review of quality of life research in medicine and health sciences","volume":"28","author":"Haraldstad","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.resmer.2022.100962_bib0012","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1477-7525-11-184","article-title":"The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice","volume":"11","author":"Calvert","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.resmer.2022.100962_bib0013","unstructured":"About PROTEUS. Accessed July 2, 2021. https:\/\/more.bham.ac.uk\/proteus\/about-proteus\/"},{"key":"10.1016\/j.resmer.2022.100962_bib0014","unstructured":"Tools and Resources For Using PROs in Clinical Trials. Accessed June 29, 2021. https:\/\/more.bham.ac.uk\/proteus\/tools-and-resources-for-using-pros-in-clinical-trials\/"},{"key":"10.1016\/j.resmer.2022.100962_bib0015","article-title":"Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals","volume":"11","author":"Turner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.resmer.2022.100962_bib0016","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.resmer.2022.100962_bib0017","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s11136-017-1508-6","article-title":"Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension","volume":"26","author":"Mercieca-Bebber","year":"2017","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.resmer.2022.100962_bib0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ebmed-2017-110713","article-title":"Guidelines for reporting meta-epidemiological methodology research","volume":"22","author":"Murad","year":"2017","journal-title":"Evid Based Med"},{"key":"10.1016\/j.resmer.2022.100962_bib0019","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","article-title":"Glanville. Chapter 6: searching for studies","author":"Lefebvre","year":"2011"},{"key":"10.1016\/j.resmer.2022.100962_bib0020","unstructured":"Hillman C., Hartwell M., Vassar M., Wise A., Heigle B., Shepard S., et al. Cystic fibrosis (July 2021). Published online June 15, 2021. Accessed July 22, 2021."},{"key":"10.1016\/j.resmer.2022.100962_bib0021","unstructured":"Cochrane Training. Accessed July 17, 2021. https:\/\/www.youtube.com\/channel\/UCoWzvKR8RPHG07PPeqBiibA"},{"key":"10.1016\/j.resmer.2022.100962_bib0022","unstructured":"Risk of Bias Tools - Current Version of RoB 2. Accessed July 21, 2021. https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/current-version-of-rob-2?authuser=0"},{"key":"10.1016\/j.resmer.2022.100962_bib0023","unstructured":"Risk of Bias Tools - RoB 2 for Crossover Trials. Accessed July 21, 2021. https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/rob-2-for-crossover-trials?authuser=0"},{"key":"10.1016\/j.resmer.2022.100962_bib0024","unstructured":"Risk of Bias Tools - RoB 2 for Cluster-Randomized Trials. Accessed July 21, 2021. https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/rob-2-for-cluster-randomized-trials?authuser=0"},{"issue":"4","key":"10.1016\/j.resmer.2022.100962_bib0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ehjqcco\/qcaa022","article-title":"Gaps in patient-reported outcome measures in randomized clinical trials of cardiac catheter ablation: a systematic review","volume":"6","author":"Chen","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.resmer.2022.100962_bib0026","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood-2019-128741","article-title":"Under reporting of patient reported outcomes (PROs) in myeloproliferative neoplasm (MPN) clinical trials","volume":"134","author":"Messina","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0027","first-page":"1","article-title":"The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders","volume":"4","author":"Rivera","year":"2020","journal-title":"J Patient-Rep Outcomes"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0028","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.resmer.2022.100962_bib0029","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-016-0483-x","article-title":"Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS\u00ae)","volume":"14","author":"Ware","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11136-020-02625-z","article-title":"International guidance on the selection of patient-reported outcome measures in clinical trials: a review","volume":"30","author":"Crossnohere","year":"2021","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.resmer.2022.100962_bib0031","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/adc.2004.058222","article-title":"Understanding randomised controlled trials","volume":"90","author":"Akobeng","year":"2005","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0032","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.200802-220OC","article-title":"Can health-related quality of life predict survival in adults with cystic fibrosis?","volume":"179","author":"Abbott","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0033","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.resmer.2022.100962_bib0034","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/medu.13130","article-title":"Reporting quality and risk of bias in randomised trials in health professions education","volume":"51","author":"Horsley","year":"2017","journal-title":"Med Educ"},{"key":"10.1016\/j.resmer.2022.100962_bib0035","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"177","article-title":"Considering bias and conflicts of interest among the included studies","author":"Boutron","year":"2019"},{"key":"10.1016\/j.resmer.2022.100962_bib0036","unstructured":"Chapter 5: Collecting data. Accessed July 26, 2021. https:\/\/training.cochrane.org\/handbook\/current\/chapter-05"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:57:45Z","timestamp":1762909065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041222000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":36,"alternative-id":["S2590041222000770"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100962","relation":{},"ISSN":["2590-0412"],"issn-type":[{"type":"print","value":"2590-0412"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SPLF and Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100962"}}